CN112771161A - 滋养层细胞表面抗原2(trop2)特异性抗体 - Google Patents

滋养层细胞表面抗原2(trop2)特异性抗体 Download PDF

Info

Publication number
CN112771161A
CN112771161A CN201980052411.6A CN201980052411A CN112771161A CN 112771161 A CN112771161 A CN 112771161A CN 201980052411 A CN201980052411 A CN 201980052411A CN 112771161 A CN112771161 A CN 112771161A
Authority
CN
China
Prior art keywords
antibody
trop2
antibodies
trop
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052411.6A
Other languages
English (en)
Chinese (zh)
Inventor
侯冰
孟逊
王娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genequantum Healthcare Suzhou Co Ltd
Original Assignee
Genequantum Healthcare Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genequantum Healthcare Suzhou Co Ltd filed Critical Genequantum Healthcare Suzhou Co Ltd
Priority to CN202111518912.4A priority Critical patent/CN114573699A/zh
Priority to CN202111506315.XA priority patent/CN114191565A/zh
Priority to CN202111506322.XA priority patent/CN114014932A/zh
Publication of CN112771161A publication Critical patent/CN112771161A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980052411.6A 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体 Pending CN112771161A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202111518912.4A CN114573699A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111506315.XA CN114191565A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111506322.XA CN114014932A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695515P 2018-07-09 2018-07-09
US62/695,515 2018-07-09
PCT/IB2019/000875 WO2020016662A2 (en) 2018-07-09 2019-06-26 Antibodies specific to trophoblast antigen 2 (trop2)

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202111518912.4A Division CN114573699A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111506322.XA Division CN114014932A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111506315.XA Division CN114191565A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体

Publications (1)

Publication Number Publication Date
CN112771161A true CN112771161A (zh) 2021-05-07

Family

ID=69165234

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111506322.XA Pending CN114014932A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111506315.XA Pending CN114191565A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111518912.4A Withdrawn CN114573699A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN201980052411.6A Pending CN112771161A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN202111506322.XA Pending CN114014932A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111506315.XA Pending CN114191565A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体
CN202111518912.4A Withdrawn CN114573699A (zh) 2018-07-09 2019-06-26 滋养层细胞表面抗原2(trop2)特异性抗体

Country Status (7)

Country Link
US (1) US20210221907A1 (https=)
EP (1) EP3821005A4 (https=)
JP (1) JP2021531826A (https=)
CN (4) CN114014932A (https=)
AU (1) AU2019304175A1 (https=)
TW (1) TW202016148A (https=)
WO (1) WO2020016662A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115536747A (zh) * 2021-06-30 2022-12-30 益科思特(北京)医药科技发展有限公司 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
WO2023241493A1 (zh) * 2022-06-14 2023-12-21 上海恒润达生生物科技股份有限公司 一种特异性结合Trop2的抗体或其抗原结合片段及其制备方法和应用
WO2024212960A1 (zh) * 2023-04-10 2024-10-17 英百瑞(杭州)生物医药有限公司 抗Trop2抗体-自然杀伤细胞偶联物及其用途

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6666264B2 (ja) 2014-04-29 2020-03-13 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． 新規安定型抗体薬物複合体の作製およびその応用
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
IL288485B2 (en) * 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
US20230101266A1 (en) * 2019-12-31 2023-03-30 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
EP4161653A1 (en) * 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
CN116589587A (zh) * 2020-06-22 2023-08-15 四川百利药业有限责任公司 一种抗trop2抗体
CN112321715B (zh) * 2020-11-03 2022-05-10 博奥信生物技术（南京）有限公司 抗trop2纳米抗体及其制备方法和应用
CN114685669A (zh) * 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
KR102917231B1 (ko) * 2021-03-08 2026-01-26 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항체 면역 작용제 접합체 및 이의 적용
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
CN115558026A (zh) * 2021-07-02 2023-01-03 和迈生物科技有限公司 抗trop2单域抗体及其应用
WO2023056240A2 (en) * 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3256048A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING A TUMOR ANTIGEN
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
IL318296A (en) * 2022-07-15 2025-03-01 Genequantum Healthcare Suzhou Co Ltd Anti-TROP2 antibody and its conjugate
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
GB202318553D0 (en) * 2023-12-05 2024-01-17 Unikum Therapeutics Aps Engineered plasmacytoid dendritic cells
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068946A2 (en) * 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015047510A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
AU2014371934B2 (en) * 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
AU2017257254B2 (en) * 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
CN105925536B (zh) * 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 Trop2嵌合抗原受体修饰的T淋巴细胞及其应用
CN107446050A (zh) * 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068946A2 (en) * 2011-11-11 2013-05-16 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU，Y.R. 等: "Construction of Trop-2-targeted chimeric antigen receptor-modified T cells and their effects" *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115536747A (zh) * 2021-06-30 2022-12-30 益科思特(北京)医药科技发展有限公司 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
WO2023273595A1 (zh) * 2021-06-30 2023-01-05 益科思特(北京)医药科技发展有限公司 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
CN115536747B (zh) * 2021-06-30 2024-08-27 益科思特(北京)医药科技发展有限公司 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用
WO2023241493A1 (zh) * 2022-06-14 2023-12-21 上海恒润达生生物科技股份有限公司 一种特异性结合Trop2的抗体或其抗原结合片段及其制备方法和应用
WO2024212960A1 (zh) * 2023-04-10 2024-10-17 英百瑞(杭州)生物医药有限公司 抗Trop2抗体-自然杀伤细胞偶联物及其用途

Also Published As

Publication number Publication date
CN114191565A (zh) 2022-03-18
JP2021531826A (ja) 2021-11-25
EP3821005A2 (en) 2021-05-19
EP3821005A4 (en) 2022-10-26
CN114573699A (zh) 2022-06-03
CN114014932A (zh) 2022-02-08
US20210221907A1 (en) 2021-07-22
WO2020016662A2 (en) 2020-01-23
WO2020016662A3 (en) 2020-04-02
AU2019304175A1 (en) 2021-03-04
TW202016148A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
US20210221907A1 (en) Antibodies specific to trophoblast antigen 2 (trop2)
US12371509B2 (en) Antibodies specific to MUC18
US12378310B2 (en) Antibodies specific to folate receptor alpha
CN113474362B (zh) 对cd44特异性的抗体
US20250367313A1 (en) Antibodies specific to muc18
CA3105415C (en) Antibodies specific to folate receptor alpha
HK40105152A (zh) 对muc18特异性的抗体
HK40060753A (en) Antibodies specific to muc18
HK40060752A (en) Antibodies specific to muc18
HK40061374A (en) Antibodies specific to cd44
HK40061374B (zh) 对cd44特异性的抗体
HK40060752B (en) Antibodies specific to muc18

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210507

WD01 Invention patent application deemed withdrawn after publication